Odulimomab
Alternative Names: 25.3; 25.3 monoclonal antibody; Anti-CD11a monoclonal antibody 25.3; Anti-LFA-1 monoclonal antibody; AntilfaLatest Information Update: 31 Mar 2022
At a glance
- Originator Immunotech
- Developer Immunotech; Sanofi
- Class Monoclonal antibodies
- Mechanism of Action CD11a antigen antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Graft-versus-host disease; Renal transplant rejection
- Discontinued Delayed graft function
Most Recent Events
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 08 May 2003 Discontinued - Preclinical for Diabetes mellitus in Japan (Intraperitoneal)
- 13 Dec 2000 SangStat has discontinued development of odulimomab for the transplant indication in Europe and North America